Oxford BioMedica and Novartis build on supply deal as CAR-T medication nears finish line
admin 6th July 2017 Uncategorised 0Swiss drugmaker Novartis expects big things from its CAR-T personalized leukemia med, including FDA approval this year, and Oxford BioMedica plans to be along for the ride. The Oxford, U.K.-based group has nailed down a new agreement with Novartis to provide the commercial supplies of the lentiviral vectors for Novartis’ first CAR-T treatment.
More: Oxford BioMedica and Novartis build on supply deal as CAR-T medication nears finish line
Source: fierce